Ascendis Pharma A/S (NASDAQ:ASND) Now Covered by Analysts at Royal Bank of Canada

Royal Bank of Canada initiated coverage on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a research report sent to investors on Wednesday, MarketBeat reports. The brokerage issued an outperform rating and a $205.00 price objective on the biotechnology company’s stock.

ASND has been the subject of several other research reports. Cantor Fitzgerald lifted their price objective on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an “overweight” rating in a research note on Tuesday, February 25th. JPMorgan Chase & Co. lifted their price target on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an “overweight” rating in a research note on Tuesday, March 18th. The Goldman Sachs Group increased their price objective on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Morgan Stanley set a $180.00 price target on Ascendis Pharma A/S in a research note on Tuesday, February 18th. Finally, UBS Group assumed coverage on Ascendis Pharma A/S in a research note on Tuesday, January 7th. They issued a “buy” rating and a $196.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat.com, Ascendis Pharma A/S has an average rating of “Moderate Buy” and an average price target of $204.67.

Ascendis Pharma A/S Trading Up 4.4 %

Shares of ASND opened at $165.05 on Wednesday. The firm’s fifty day simple moving average is $152.00 and its two-hundred day simple moving average is $138.20. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $169.37. The stock has a market capitalization of $10.06 billion, a P/E ratio of -23.25 and a beta of 0.54.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($1.32) by $0.64. As a group, research analysts predict that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Institutional Trading of Ascendis Pharma A/S

Several institutional investors have recently made changes to their positions in the company. Public Employees Retirement System of Ohio purchased a new position in Ascendis Pharma A/S during the third quarter worth about $1,101,000. Wilmington Savings Fund Society FSB purchased a new position in shares of Ascendis Pharma A/S in the 3rd quarter worth approximately $30,000. Exome Asset Management LLC boosted its stake in shares of Ascendis Pharma A/S by 119.2% in the 3rd quarter. Exome Asset Management LLC now owns 43,849 shares of the biotechnology company’s stock worth $6,547,000 after buying an additional 23,849 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Ascendis Pharma A/S by 58.0% in the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 214 shares in the last quarter. Finally, Diversified Trust Co increased its position in shares of Ascendis Pharma A/S by 7.4% during the fourth quarter. Diversified Trust Co now owns 45,038 shares of the biotechnology company’s stock valued at $6,200,000 after acquiring an additional 3,114 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.